Skip to main content
D.Western Therapeutics Institute, Inc. logo

D.Western Therapeutics Institute, Inc. — Investor Relations & Filings

Ticker · 4576 ISIN · JP3548740004 T Professional, scientific and technical activities
Open in API
Filings indexed 69 across all filing types
Latest filing 2023-03-30 Audit Report / Informat…
Country JP Japan
Listing T 4576

About D.Western Therapeutics Institute, Inc.

https://dwti.co.jp/english/

D.Western Therapeutics Institute, Inc. is a biotechnology company focused on the research, discovery, and development of innovative pharmaceutical drugs. The company's core technology is centered on a proprietary compound library with a primary focus on inhibitors, particularly protein kinase inhibitors. Its drug discovery and development business aims to provide patients with more effective and beneficial treatments than conventional drugs. A notable product developed from its research is the ophthalmic solution GLANATEC.

Recent filings

Filing Released Lang Actions
確認書
Audit Report / Information Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1, in Japan. This is a mandatory regulatory filing that accompanies the Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents. Since it is a specific regulatory filing required by law that does not fit into the primary financial report categories (like 10-K or IR) and is not a mere announcement of a report, it falls under the general regulatory filings category. FY 2022
2023-03-30 Japanese
内部統制報告書－第25期(2022/01/01－2022/12/31)
Governance Information Classification · 1% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. This type of report details the company's internal control framework, evaluation scope, and results regarding financial reporting. Since it is a specific regulatory filing concerning internal controls and does not fit into the other categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2023-03-30 Japanese
有価証券報告書－第25期(2022/01/01－2022/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains detailed financial statements, business overviews, and management indicators for the fiscal year ending December 31, 2022. It is a comprehensive annual filing submitted to the Tokai Finance Bureau, not an announcement or a summary. FY 2022
2023-03-30 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is titled 'Confirmation Letter' (確認書) and is filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO confirming the accuracy of the quarterly report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements. Q3 2022
2022-11-10 Japanese
四半期報告書－第25期第3四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Tokai Finance Bureau in Japan, covering the third quarter of the 25th fiscal period (July 1, 2022, to September 30, 2022). It contains detailed financial statements, management analysis (MDA), and information on share capital and stock options. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q3 2022
2022-11-10 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan. This is a mandatory regulatory filing that accompanies a Quarterly Report (Interim Report) to confirm the accuracy of the financial statements. Since it is a specific regulatory filing required by law to accompany the financial report, and it does not contain the full financial report itself, it falls under the category of Regulatory Filings (RNS).
2022-08-09 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.